[1] | Akbar SM, Horiike N, and Onji M; 2006, Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection. World J Gastroenterol; 12:2876–83. |
[2] | Allain JP, Dong Y, Vandamme AM, Moulton V, and Salemi M; 2000, Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters. J Virol; 74: 2541-2549. |
[3] | Alter MJ; 1997, Epidemiology of hepatitis C. Hepatology; 26: 62S-65S. |
[4] | Arvin AM, and Greenberg HB; 2006, New viral vaccines. Virology; 344: 240-249. |
[5] | Auffermann-Gretzinger S, Keeffe EB, and Levy S; 2001, Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood; 97:3171–6. |
[6] | Bain C, Fatmi A, Zoulim F, Zarski JP, Trépo C, and Inchauspé G; 2001, Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology; 120: 512-524. |
[7] | Banchereau J, and Steinman RM; 1998, Dendritic cells and the control of immunity. Nature; 392:245–52. |
[8] | Bartosch B, Dubuisson J, Cosset FL; 2003, Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med; 197: 633-642. |
[9] | Baumert TF, Ito S, Wong DT, and Liang TJ; 1998, Hepatitis C virus structural proteins assemble into virus like particles in insect cells. J Virol; 72: 3827-3836. |
[10] | Beckebaum S, Cicinnati VR, Dworacki G, Muller-Berghaus J, Stolz D, Harnaha J, et al; 2002, Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol; 104:138–50. |
[11] | Beckebaum S, Cicinnati VR, Zhang X, Ferencik S, Frilling A, Grosse-Wilde H, et al; 2003, Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology, 109:487–95. |
[12] | Boonstra A, Woltman AM, and Janssen HL; 2008, Immunology of hepatitis B and hepatitis C virus infections. Best Pract Res Clin Gastroenterol; 22:1049–61. |
[13] | Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger K, Thudium K, Kuo C; 1994, Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA; 91: 1294-1298. |
[14] | Cohen J; 1999, The scientific challenge of hepatitis C. Science; 285: 26-30. |
[15] | Cohen S, Haimovich J, and Hollander N; 2009, Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma. J Immunol; 182:1667–73. |
[16] | Díaz-Valdés N, Manterola L, Belsúe V, Riezu-Boj JI, Larrea E, Echeverria I, Llópiz D, López-Sagaseta J, Lerat H, Pawlotsky JM, Prieto J, Lasarte JJ, Borrás-Cuesta F, Sarobe P; 2011, Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology; 53: 23-31. |
[17] | Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, Scholz S, Santantonio T, Houghton M, Southwood S, Sette A, and Pape GR; 1997, Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol; 71: 6011-6019. |
[18] | Duan XZ, Zhuang H, Wang M, Li HW, Liu JC, and Wang FS; 2005, Decreased numbers and impaired function of circulating dendritic cell subsets in patients with chronic hepatitis B infection (R2). J Gastroenterol Hepatol; 20:234-42. |
[19] | Encke, J, Findeklee J, Geib J, Pfaff E, and Stremmel W; 2005, Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clinical and Experimental Immunology; 142:362-369. |
[20] | Farag MM, Hoyler B, Encke J, Stremmel W, Weigand K; 2010, Dendritic cells can effectively be pulsed by HBVsvp and induce specific immune reactions in mice. Vaccine; 29: 200-206. |
[21] | Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, Shapiro M, Alter HJ, and Purcell RH; 1996, Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA; 93: 15394-15399. |
[22] | Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin, A, Hoffman J, and Yu J; 2002, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med; 347: 975-982. |
[23] | Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, and Plebanski M; 2004, Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol; 82: 506-516. |
[24] | Garcia F, Lejeune M, Climent N, Gil C, Alcami J, Morente V, Alos L, Ruiz A, Setoain J, Fumero E, Castro P, Lopez A, Cruceta A, Piera C, Florence E, Pereira A, Libois A, Gonzalez N, Guila M, Caballero M, Lomena F, Joseph J, Miro JM, Pumarola T, Plana M, Gatell JM, and Gallart T; 2005, Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis.; 191:1680-5. |
[25] | Hong Y, Huang H, Xiang J, Babiuk LA, and van Drunen Littel-van den Hurk S; 2006, Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3. J Gen Virol; 87:1-10. |
[26] | Houghton M, Abrignani S; 2005, Prospects for a vaccine against the hepatitis C virus. Nature; 436: 961-966. |
[27] | Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al; 1992, Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med; 176:1693–702. |
[28] | Kakumu S, Ito S, Ishikawa T, et al; 2002, Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol, 15:431–6. |
[29] | Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, and Muthuswamy R; 2009, Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncol; 5: 379-390. |
[30] | Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, Sasaki Y, Kasahara A, Hori M; 1999, Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol; 162: 5584-5591. |
[31] | Koutsoudakis G, Kaul A, Steinmann E, et al; 2006, Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol; 80:5308–20. |
[32] | Lamonaca V, Missale G, Urbani S, Pilli M, Boni C, Mori C, Sette A, Massari M, Southwood S, Bertoni R, Valli A, Fiaccadori F, and Ferrari C; 1999, Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology; 30: 1088-1098. |
[33] | Landi A, Yu H, Babiuk LA, and van Drunen Littel-van den Hurk S; 2011, Human dendritic cells expressing hepatitis C virus core protein display transcriptional and functional changes consistent with maturation. J Viral Hepat; 18: 700-713. |
[34] | Langhans B, Braunschweiger I, Schweitzer S, Jung G, Inchauspé G, Sauerbruch T, Spengler U; 2001, Lipidation of T helper sequences from hepatitis C virus core significantly enhances T-cell activity in vitro. Immunology; 102: 460-465. |
[35] | Lanzavecchia A, and Sallusto F; 2001, Antigen decoding by T lymphocytes: from synapses to fate determination. Nat Immunol; 2:487–92. |
[36] | Lanzavecchia A, and Sallusto F; 2001, Regulation of T cell immunity by dendritic cells. Cell; 106:263–6. |
[37] | Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M, Dusheiko G, Allen TM, Chung RT, Walker BD, and Klenerman P; 2004, High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology; 127: 924-936. |
[38] | Ma XJ, Tian DY, Xu D, Yang DF, Zhu HF, Liang ZH, et al; 2007, Uric acid enhances T cell immune responses to hepatitis B surface antigen-pulsed-dendritic cells in mice. World J Gastroenterol; 13:1060–6. |
[39] | Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK; 2001, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet; 358: 958-965. |
[40] | Moretta A; 2002, Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol, 2:957–64. |
[41] | Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ; 2003, Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA; 100: 6753-6758. |
[42] | Nègre D, Duisit G, Mangeot PE, Moullier P, Darlix JL, Cosset FL; 2002, Lentiviral vectors derived from simian immunodeficiency virus (SIV). Curr. Top. Microbiol. Immunol; 261: 53–74. |
[43] | Onaitis M, Kalady MF, Pruitt S, and Tyler DS; 2002, Dendritic cell gene therapy. Surg Oncol Clin N Am; 11: 645-660. |
[44] | Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL, van der Molen RG, et al; 2009, Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology; 126:280–9. |
[45] | Oseroff C, Sette A, Wentworth P, Celis E, Maewal A, Dahlberg C, Fikes J, Kubo RT, Chesnut RW, Grey HM, Alexander J; 1998, Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses. Vaccine; 16: 823-833. |
[46] | Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, and Baumert TF; 2007, Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA; 104: 6025-6030. |
[47] | [47] Phillipps KS, Wykes MN Liu XQ, Brown M, Blanchfield J, and Toth IA; 2009, novel synthetic adjuvant enhances dendritic cell function. Immunology; 128: 582-588. |
[48] | Pietschmann T, Zayas M, Meuleman P, et al; 2009, Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Path; 5:e1000475. |
[49] | Pulendran B, Palucka K, and Banchereau J; 2001, Sensing pathogens and tuning immune responses. Science; 293: 253–6. |
[50] | Qiu SJ, Lu L, Qiao C, Wang L, Wang Z, Xiao X, et al; 2005, Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization. J Cancer Res Clin Oncol; 131:429–38. |
[51] | Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV; 1996, Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest; 98: 1432-1440. |
[52] | Rinaldo CR; 2009, Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med; 265: 138-158. |
[53] | Sandrin V, Boson B, Salmon P, Gay W, Nègre D, Grand RL, Trono D, and Cosset FL; 2002, Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34 cells derived from human and non-human primates. Blood; 100: 823–832. |
[54] | Sarobe P, Lasarte JJ, Casares N, López-Díaz de Cerio A, Baixeras E, Labarga P, García N, Borrás-Cuesta, F, Prieto J; 2002, Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol; 76: 5062-5070. |
[55] | Schulze zur, Wiesch J, Lauer GM, Day CL, Kim AY, Ouchi K, Duncan JE, Wurcel, AG, Timm J, Jones AM, Mothe B, Allen TM, McGovern B, Lewis-Ximenez L, Sidney J, Sette A, Chung RT, and Walker BD; 2005, Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol; 175: 3603-3613. |
[56] | Shi M, Fu J, Shi F, Zhang B, Tang Z, Zhang Z, et al; 2009, Viral suppression correlates with dendritic cell restoration in chronic hepatitis B patients with autologous cytokine-induced killer cell transfusion. Liver Int; 29:466–74. |
[57] | Spada E, Mele A, Berton A, Ruggeri L, Ferrigno L, Garbuglia AR, Perrone MP, Girelli G, Del Porto P, Piccolella E, Mondelli MU, Amoroso P, Cortese R, Nicosia A, Vitelli A, and Folgori A; 2004, Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut; 53: 1673-1681. |
[58] | Steinman RM; 1991, The dendritic cell system and its role in immunogenicity. Annu Rev Immunol; 9:271–96. |
[59] | Steinman RM, Hawiger D, and Nussenzweig MC; 2003, Tolerogenic dendritic cells. Annu Rev Immunol; 21:685–711. |
[60] | Torresi, J, Bharadwaj M, Jackson DC, and Gowans EJ; 2004, Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy. Curr Drug Targets; 5: 41-56. |
[61] | Torresi J, Johnson D, and Wedemeyer H; 2011, Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol; 54:1273-1285. |
[62] | van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HG, Kusters JG, et al; 2004, Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology; 40:738–46. |
[63] | Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H, and Rehermann B; 2002, Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol; 169: 3447-3458. |
[64] | Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, Bonino F, Saracco G, Choo QL, Houghton M; 1991. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology; 180: 842-848. |
[65] | Zanoni I, Ostuni R, Capuano G, Collini M, Caccia M, Ronchi AE, et al; 2009, CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature. |
[66] | Zein NN; 2000, Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev; 13:223–235. |